Clinical progress and transmission perils stressed at second human retroviruses conference. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Clinical progress and transmission perils stressed at second human retroviruses conference. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

J Int Assoc Physicians AIDS Care. 1995 Mar;1(2):19-29. Unique Identifier : AIDSLINE AIDS/95700334
Mascolini M

Abstract: The Second Human Retroviruses Conference covered many topics, including statistics on the viruses' prevalence in American society and some survey results on sexual behavior. Conference meetings were dominated by discussions on protease inhibitors and current clinical trial data on two inhibitors in particular, 3TC and ZDV. Evidence of a new herpes virus causing Kaposi's sarcoma (KS), and research on anti-KS agents, were discussed, including assessments concerning the struggle between the virus and the immune system, and arguments about using immune-based therapies versus attacking the virus directly. Of particular interest concerning immune-based therapy was the National Institute of Allergy and Infectious Diseases' (NIAID) interleukin-2 trial which is showing impressive results in affecting CD4+ counts, if CD4+ counts are not too low initially. Antiretroviral information centered on two investigations surrounding Parke-Davis' PD121871 and PD144975, which seem to prevent activation of latently-infected cells, and return activated cells to a quiescent state. Other conference topics covered acyclovir survival levels, the new therapies and renewed concerns about cytomegalovirus, planning an overall prophylactic strategy, the slow progress in developing a vaccine, and whether low-dose chemotherapy for lymphoma was as good as the standard dose.

Keywords: Acyclovir/THERAPEUTIC USE Antineoplastic Agents/THERAPEUTIC USE Antiviral Agents/THERAPEUTIC USE AIDS Vaccines AIDS-Related Opportunistic Infections/PREVENTION & CONTROL Cytomegalovirus Retinitis/DRUG THERAPY CD4 Lymphocyte Count Herpesviridae/ISOLATION & PURIF Human *HIV Infections/DRUG THERAPY/EPIDEMIOLOGY/IMMUNOLOGY Interleukin-2/THERAPEUTIC USE Lymphoma, Non-Hodgkin's/DRUG THERAPY *Retroviridae Sarcoma, Kaposi's/VIROLOGY Zalcitabine/THERAPEUTIC USE Zidovudine/THERAPEUTIC USE NEWSLETTER ARTICLE

951130
M95B0921

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .